

## RS2124 - Infliximab

Crohn's disease (adults) - INITIATION .....	6
Crohn's disease (adults) - CONTINUATION .....	6
Crohn's disease (children) - INITIATION .....	6
Crohn's disease (children) - CONTINUATION .....	7
Graft vs host disease - INITIATION .....	2
Inflammatory bowel arthritis (axial) - INITIATION .....	12
Inflammatory bowel arthritis (axial) - CONTINUATION .....	12
Inflammatory bowel arthritis (peripheral) - INITIATION .....	13
Inflammatory bowel arthritis (peripheral) - CONTINUATION .....	13
Pulmonary sarcoidosis - INITIATION .....	5
Acute fulminant ulcerative colitis - INITIATION .....	8
Ankylosing spondylitis - INITIATION .....	2
Ankylosing spondylitis - CONTINUATION .....	3
Chronic ocular inflammation - INITIATION .....	5
Chronic ocular inflammation - CONTINUATION .....	5
Fistulising Crohn's disease - INITIATION .....	7
Fistulising Crohn's disease - CONTINUATION .....	7
Fulminant ulcerative colitis - CONTINUATION .....	8
Immune checkpoint inhibitor toxicity in malignancy* - INITIATION .....	13
Immune checkpoint inhibitor toxicity in malignancy* - CONTINUATION .....	14
Neurosarcoidosis - INITIATION .....	10
Neurosarcoidosis - CONTINUATION .....	11
Plaque psoriasis - INITIATION .....	9
Plaque psoriasis - CONTINUATION .....	10
Psoriatic arthritis - INITIATION .....	3
Psoriatic arthritis - CONTINUATION .....	3
Pyoderma gangrenosum - INITIATION .....	12
Pyoderma gangrenosum - CONTINUATION .....	12
Rheumatoid arthritis - INITIATION .....	2
Rheumatoid arthritis - CONTINUATION .....	2
Severe Behcet's disease - INITIATION .....	11
Severe Behcet's disease - CONTINUATION .....	11
Severe ocular inflammation - INITIATION .....	4
Severe ocular inflammation - CONTINUATION .....	4
Ulcerative colitis - INITIATION .....	8
Ulcerative colitis - CONTINUATION .....	9

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab**

**INITIATION – Graft vs host disease**

**Prerequisites** (tick box where appropriate)

- ☐ Patient has steroid-refractory acute graft vs. host disease of the gut

**INITIATION – rheumatoid arthritis**

Re-assessment required after 4 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis

and

- ☐ The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept

or

- ☐ Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept

and

- ☐ Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

**CONTINUATION – rheumatoid arthritis**

Re-assessment required after 6 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

and

- ☐ Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

or

- ☐ The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician

and

- ☐ Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks

**INITIATION – ankylosing spondylitis**

Re-assessment required after 3 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis

and

- ☐ The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept

or

- ☐ Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab** - continued

**CONTINUATION – ankylosing spondylitis**

Re-assessment required after 6 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less

and

- ☐ Physician considers that the patient has benefited from treatment and that continued treatment is appropriate

and

- ☐ Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks

**INITIATION – psoriatic arthritis**

Re-assessment required after 4 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ The patient has had an initial Special Authority approval for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis

and

- ☐ The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept and/or secukinumab
- ☐ Following 3-4 months' initial treatment with adalimumab and/or etanercept and/or secukinumab, the patient did not meet the renewal criteria for adalimumab and/or etanercept and/or secukinumab for psoriatic arthritis.

**CONTINUATION – psoriatic arthritis**

Re-assessment required after 6 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a rheumatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- ☐ The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician

and

- ☐ Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab** - continued

**INITIATION – severe ocular inflammation**

Re-assessment required after 4 months

**Prerequisites** (tick boxes where appropriate)

☐ The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation

and

☐ The patient has experienced intolerable side effects from adalimumab

or

☐ The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation

or

☐ Patient has severe, vision-threatening ocular inflammation requiring rapid control

and

☐ Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms

or

☐ Patient developed new inflammatory symptoms while receiving high dose steroids

or

☐ Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms

**CONTINUATION – severe ocular inflammation**

Re-assessment required after 12 months

**Prerequisites** (tick boxes where appropriate)

☐ The patient has had a good clinical response following 3 initial doses

or

☐ Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema)

or

☐ Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab** - continued

**INITIATION – chronic ocular inflammation**

Re-assessment required after 4 months

**Prerequisites** (tick boxes where appropriate)

☐ The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation

and

☐ The patient has experienced intolerable side effects from adalimumab

or

☐ The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation

or

☐ Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss

and

☐ Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective

or

☐ Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose

or

☐ Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate

**CONTINUATION – chronic ocular inflammation**

Re-assessment required after 12 months

**Prerequisites** (tick boxes where appropriate)

☐ The patient has had a good clinical response following 3 initial doses

or

☐ Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema)

or

☐ Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

**INITIATION – Pulmonary sarcoidosis**

**Prerequisites** (tick boxes where appropriate)

☐ Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments

and

☐ Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab - continued**

**INITIATION – Crohn's disease (adults)**

Re-assessment required after 6 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has active Crohn's disease

and

- ☐ Patient has a CDAI score of greater than or equal to 300, or HBI score of greater than or equal to 10
- or
- ☐ Patient has extensive small intestine disease affecting more than 50 cm of the small intestine
- or
- ☐ Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection
- or
- ☐ Patient has an ileostomy or colostomy, and has intestinal inflammation

and

- ☐ Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior therapy with immunomodulators and corticosteroids

**CONTINUATION – Crohn's disease (adults)**

Re-assessment required after 2 years

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ CDAI score has reduced by 100 points from the CDAI score, or HBI score has reduced by 3 points, from when the patient was initiated on infliximab
- or
- ☐ CDAI score is 150 or less, or HBI is 4 or less
- or
- ☐ The patient has demonstrated an adequate response to treatment but CDAI score and/or HBI score cannot be assessed

and

- ☐ Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle

**INITIATION – Crohn's disease (children)**

Re-assessment required after 6 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Paediatric patient has active Crohn's disease

and

- ☐ Patient has a PCDAI score of greater than or equal to 30
- or
- ☐ Patient has extensive small intestine disease

and

- ☐ Patient has tried but experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and corticosteroids

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab - continued**

**CONTINUATION – Crohn's disease (children)**

Re-assessment required after 2 years

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab
- or
- ☐ PCDAI score is 15 or less
- or
- ☐ The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed

and

- ☐ Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle

**INITIATION – fistulising Crohn's disease**

Re-assessment required after 6 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has confirmed Crohn's disease
- and
- ☐ Patient has one or more complex externally draining enterocutaneous fistula(e)
- or
- ☐ Patient has one or more rectovaginal fistula(e)
- or
- ☐ Patient has complete peri-anal fistula

**CONTINUATION – fistulising Crohn's disease**

Re-assessment required after 2 years

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ The number of open draining fistulae have decreased from baseline by at least 50%
- or
- ☐ There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain

and

- ☐ Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab - continued**

**INITIATION – acute fulminant ulcerative colitis**

Re-assessment required after 6 weeks

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a gastroenterologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has acute, fulminant ulcerative colitis
- and
- ☐ Treatment with intravenous or high dose oral corticosteroids has not been successful

**CONTINUATION – fulminant ulcerative colitis**

Re-assessment required after 2 years

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months
- and
- ☐ Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle

**INITIATION – ulcerative colitis**

Re-assessment required after 6 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has active ulcerative colitis
- and
- ☐ Patients SCCAI is greater than or equal to 4
- or
- ☐ Patients PUCAI score is greater than or equal to 20

and

- ☐ Patient has experienced an inadequate response to, or intolerable side effects from, prior therapy with immunomodulators and systemic corticosteroids

I confirm that the above details are correct:

Signed: ..... Date: .....



Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab - continued**

**CONTINUATION – ulcerative colitis**

Re-assessment required after 2 years

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab  
or  
☐ The PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab

and

- ☐ Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle

**INITIATION – plaque psoriasis**

Re-assessment required after 3 doses

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has had an initial Special Authority approval for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis

and

- ☐ Patient has experienced intolerable side effects from adalimumab, etanercept or secukinumab  
or  
☐ Patient has received insufficient benefit from adalimumab, etanercept or secukinumab to meet the renewal criteria for adalimumab, etanercept or secukinumab for severe chronic plaque psoriasis

or

- ☐ Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis  
or  
☐ Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis  
or  
☐ Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, and with a Dermatology Life Quality Index (DLQI) score greater than 10

and

- ☐ Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin

and

- ☐ A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course

and

- ☐ The most recent PASI assessment is no more than 1 month old at the time of initiation

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand, foot, genital or flexural areas at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and for the face, palm of a hand or sole of a foot the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab** - continued

**CONTINUATION – plaque psoriasis**

Re-assessment required after 3 doses

**Prerequisites** (tick boxes where appropriate)

- ☐ Patient had "whole body" severe chronic plaque psoriasis at the start of treatment  
**and** ☐ Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value

**or**

- ☐ Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment  
**and** ☐ Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values  
**or** ☐ Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value

**or**

- ☐ Patient had severe chronic localised genital or flexural plaque psoriasis at the start of treatment  
**and** ☐ The patient has experienced a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value  
**or** ☐ Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing infliximab

**and**

- ☐ Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks

**INITIATION – neurosarcoidosis**

Re-assessment required after 18 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

**and**

- ☐ Biopsy consistent with diagnosis of neurosarcoidosis  
**and** ☐ Patient has CNS involvement  
**and** ☐ Patient has steroid-refractory disease  
**and**

- ☐ IV cyclophosphamide has been tried  
**or** ☐ Treatment with IV cyclophosphamide is clinically inappropriate

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab - continued**

**CONTINUATION – neurosarcoidosis**

Re-assessment required after 18 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a neurologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ A withdrawal period has been tried and the patient has relapsed

or

- ☐ A withdrawal period has been considered but would not be clinically appropriate

and

- ☐ There has been a marked reduction in prednisone dose

and

- ☐ There has been an improvement in MRI appearances

or

- ☐ Marked improvement in other symptomology

**INITIATION – severe Behcet's disease**

Re-assessment required after 4 months

**Prerequisites** (tick boxes where appropriate)

- ☐ The patient has severe Behcet's disease which is significantly impacting the patient's quality of life (see Notes)

and

- ☐ The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes)

or

- ☐ The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes)

and

- ☐ The patient is experiencing significant loss of quality of life

Note:

- a) Behcet's disease diagnosed according to the International Study Group for Behcet's Disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al J Rheumatol. 2004;31:931-7.
- b) Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

**CONTINUATION – severe Behcet's disease**

Re-assessment required after 6 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Patient has had a good clinical response to initial treatment with measurably improved quality of life

and

- ☐ Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab - continued**

**INITIATION – pyoderma gangrenosum**

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has pyoderma gangrenosum\*

and

- ☐ Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response

and

- ☐ A maximum of 8 doses

Note: Indications marked with \* are unapproved indications.

**CONTINUATION – pyoderma gangrenosum**

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a dermatologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has shown clinical improvement

and

- ☐ Patient continues to require treatment

and

- ☐ A maximum of 8 doses

**INITIATION – Inflammatory bowel arthritis (axial)**

Re-assessment required after 6 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Patient has a diagnosis of active ulcerative colitis or active Crohn's disease

and

- ☐ Patient has had axial inflammatory pain for six months or more

and

- ☐ Patient is unable to take NSAIDs

and

- ☐ Patient has unequivocal sacroiliitis demonstrated by radiological imaging or MRI

and

- ☐ Patient has not experienced an adequate response to prior treatment consisting of at least 3 months of an exercise regime supervised by a physiotherapist

and

- ☐ Patient has a BASDAI of at least 6 on a 0-10 scale completed after the 3 month exercise trial, but prior to ceasing any previous pharmacological treatment

**CONTINUATION – Inflammatory bowel arthritis (axial)**

Re-assessment required after 2 years

**Prerequisites** (tick box where appropriate)

- ☐ Where treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10-point scale, or an improvement in BASDAI of 50%, whichever is less

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab - continued**

**INITIATION – Inflammatory bowel arthritis (peripheral)**

Re-assessment required after 6 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Patient has a diagnosis of active ulcerative colitis or active Crohn's disease
- and
- ☐ Patient has active arthritis in at least four joints from the following: hip, knee, ankle, subtalar, tarsus, forefoot, wrist, elbow, shoulder, sternoclavicular
- and
- ☐ Patient has tried and not experienced a response to at least three months of methotrexate or azathioprine at a maximum tolerated dose (unless contraindicated)
- and
- ☐ Patient has tried and not experienced a response to at least three months of sulfasalazine at a maximum tolerated dose (unless contraindicated)
- and
- ☐ Patient has a CRP level greater than 15 mg/L measured no more than one month prior to the date of this application
- or
- ☐ Patient has an ESR greater than 25 mm per hour measured no more than one month prior to the date of this application
- or
- ☐ ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months

**CONTINUATION – Inflammatory bowel arthritis (peripheral)**

Re-assessment required after 2 years

**Prerequisites** (tick boxes where appropriate)

- ☐ Following initial treatment, patient has experienced at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician
- or
- ☐ Patient has experienced at least a continuing 30% improvement in active joint count from baseline in the opinion of the treating physician

**INITIATION – immune checkpoint inhibitor toxicity in malignancy\***

Re-assessment required after 4 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.
- and
- ☐ The individual requires treatment for moderate to severe autoimmune toxicity following immune checkpoint inhibitor treatment for malignancy
- and
- ☐ The individual has received insufficient benefit from use of corticosteroids
- and
- ☐ Infliximab is to be administered at up to 5mg/kg for up to four doses

I confirm that the above details are correct:

Signed: ..... Date: .....

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Infliximab** - *continued*

**CONTINUATION – immune checkpoint inhibitor toxicity in malignancy\***

Re-assessment required after 4 months

**Prerequisites** (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ The individual has shown clinical improvement and ongoing treatment is required
- and ☐ Infliximab is to be administered at up to 5mg/kg for up to a total of 8 doses

Note: Indications marked with \* are unapproved indications.

I confirm that the above details are correct:

Signed: ..... Date: .....